In this issue:
LD dysfunction and 2-year outcomes in type 2 diabetes
Saxagliptin and CV outcomes in type 2 diabetes
Alogliptin after acute coronary syndrome in type 2 diabetes
Canagliflozin vs. sitagliptin for inadequate diabetes control with metformin + sulfonylurea
Adding lixisenatide for inadequate diabetes control with basal insulin
Smoking during pregnancy and daughters’ gestational diabetes/obesity risk
Triple antioxidant therapy in type 1 diabetes
BP variability and diabetic nephropathy risk in type 2 diabetes
HbA1c level changes associated with high-sensitivity CRP changes
Empagliflozin in type 2 diabetes
Please login below to download this issue (PDF)